Seeking Alpha

Osiris shares jump following study results for Grafix

  • Osiris Therapeutics (OSIR) leaps 57% after saying its stem-cell based biosurgery product Grafix closed three times as many wounds as conventional treatment in a study of patients with a diabetic foot ulcer.
  • In the trial, 62% of patients receiving Grafix enjoyed complete wound closure vs only 21% who received standard care.
  • Grafix also closed wounds faster and needed fewer treatments.
  • Around a quarter of diabetics develop diabetic foot ulcers. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector